

Korea explores AI support for prostate cancer diagnosis

11 October 2022 | News

DeepDx-Prostate Pro, designated as an Innovative Product by the Korea Public Procurement Service, is expected to improve pathology workflows in real clinical settings

South Korea-based startup Deep Bio Inc. has announced that it will sign trial purchase agreements with five Korean hospitals for its artificial intelligence (AI)-based prostate cancer diagnosis support software, DeepDx-Prostate Pro, through the Public Procurement Marketplace programme run by the Korean Public Procurement Service (PPS). The software was designated as an 'Innovative Product'.

To successfully complete the integration of DeepDx-Prostate Pro into the pathology workflows by this November, the hospitals participating in the trial purchase - the SMG-SNU Boramae Medical Center, Chungnam National University Sejong Hospital, Korea Institute of Radiological & Medical Sciences, Jeju National University Hospital, and Gyeongsang National University Changwon Hospital – and Deep Bio are progressing through required procedures and making arrangements. The AI will be used for various purposes, including support for pathologists in tumor severity determination, confirmation of diagnoses, and research.

DeepDx-Prostate Pro is a deep learning-based medical software that assists the histopathological diagnosis of prostate cancer by analyzing the Whole Slide Image (WSI) of the prostate needle biopsies. It automatically classifies the severity of prostate cancer, which empowers pathologists to make diagnostic decisions with increased accuracy and speed.